Children are highly susceptible to influenza and are at high risk for severe cases. Chinese patent medicine (CPM) offers advantages in treating pediatric influenza, but the issue of its improper use is increasingly prevalent in clinical practice. To address this, we adopted a dual leadership approach involving clinical and methodological experts, guided by evidence-based and clinical practice principles. We referred to existing guidelines, consensus statements, and treatment protocols, and designed relevant clinical questions based on the “3 specific” principles: specific CPM, specific disease stages, and specific outcomes. This allowed us to conduct evidence-based evaluations of the efficacy and application of CPMs specifically designed for children or with pediatric dosages. Using the “Checklist for Reporting Clinical Practice Guidelines for Chinese Patent Medicines V1.0” developed by our research team, we formulated recommendations for CPM. Ultimately, 13 CPMs were recommended, providing clinicians with references on “how to select medication” and “how to use medication.”